Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.

Publication

Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.

Journal Paper/Review - Jan 25, 2023

Mohebbi Nilufar, Ritter Alexander, Wiegand Anna, Graf Nicole, Dahdal Suzan, Sidler Daniel, Arampatzis Spyridon, Hadaya Karine, Müller Thomas F, Wagner Carsten A, Wüthrich Rudolf P

Citation

Mohebbi N, Ritter A, Wiegand A, Graf N, Dahdal S, Sidler D, Arampatzis S, Hadaya K, Müller T, Wagner C, Wüthrich R. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401:557-567.

Type

Journal Paper/Review (English)

Journal

Lancet 2023; 401

Publication Date

Jan 25, 2023

Issn Electronic

1474-547X

Pages

557-567

Brief description/objective

Metabolic acidosis is common in kidney transplant recipients and is associated with declining graft function. Sodium bicarbonate treatment effectively corrects metabolic acidosis, but no prospective studies have examined its effect on graft function. Therefore, we aimed to test whether sodium bicarbonate treatment would preserve graft function and slow the progression of estimated glomerular filtration rate (GFR) decline in kidney transplant recipients.